title: Five-year follow-up of saliva in patients treated for lymphomas.
abstract: OBJECTIVE
  Patients treated for Hodgkin's disease and non-Hodgkin lymphomas were followed for 5 years after start of therapy. The patients received combinations of anticancer drugs for curative intent for 6 months (Hodgkin's disease) or 7 months (non-Hodgkin lymphomas).
  
  
  METHODS
  Cumulated data of 22 surviving patients (mean age, 49 years) were compared with that of 17 patients (mean age, 52 years) who had died or were terminally ill at the 5-year examination. Saliva samples were taken at baseline, and 4, 6, 12, and 60 months after start of chemotherapy. Salivary flow rate and a variety of biochemical constituents were analyzed.
  
  
  RESULTS
  The results showed no long-term effect of anticancer treatment on salivary flow rates. Neither was there any difference between the surviving or deceased patients' baseline values (1.5 +/- 0.7 mL/minute versus 1.5 +/- 0.8 mL/minute) and after chemotherapy. Lysozyme, IgA, IgG, and IgM concentrations decreased after chemotherapy. Significantly lower values were observed at the 5-year examination than at baseline. This was particularly evident in IgA, which is the major immunoglobulin in saliva; mean IgA was 70.5 +/- 52.8 mg/mL at baseline, 35.8 +/- 15.0 mg/mL 5 years later (p < 0.001). Salivary total protein and amylase concentrations were significantly decreased (p < 0.001 and p < 0.05, respectively), whereas albumin concentration was significantly increased at the 5-year examination (p < 0.05). When the salivary biochemical results were compared between the surviving and deceased patients, no statistically significant differences were observed. At baseline, however, the mean immunoglobulin values were lower in patients who later died, in comparison with those who survived.
  
  
  CONCLUSIONS
  These results showed that modern anticancer therapy need not cause severe side effects on salivary flow rates and composition. In addition, apart from the long-term immunosuppression, no significant decreases were expressed in salivary defensive factors.
authors.affiliation: Institute of Dentistry, University of Helsinki, Finland.
authors.forename: J H
authors.initials: JH
authors.lastname: Meurman
authors.forename: P
authors.initials: P
authors.lastname: Laine
authors.forename: S
authors.initials: S
authors.lastname: Keinànen
authors.forename: S
authors.initials: S
authors.lastname: Pyrhönen
authors.forename: L
authors.initials: L
authors.lastname: Teerenhovi
authors.forename: C
authors.initials: C
authors.lastname: Lindqvist
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000418:Albumins / Q000032:analysis; D000681:Amylases / Q000032:analysis; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology* / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000032:analysis; D002955:Leucovorin / Q000008:administration & dosage; D008223:Lymphoma / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009113:Muramidase / Q000032:analysis; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D012463:Saliva / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism; D012471:Salivary Proteins and Peptides / Q000032:analysis / Q000187:drug effects; D012636:Secretory Rate / Q000187:drug effects; D018709:Statistics, Nonparametric; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000418:Albumins; D007071:Immunoglobulin A, Secretory; D012471:Salivary Proteins and Peptides; D001761:Bleomycin; D011344:Procarbazine; D015251:Epirubicin; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D000681:Amylases; D009113:Muramidase; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate